Back to Browse Journals » Clinical Ophthalmology » Volume 4

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations

Authors Emilio Rintaro Suzuki Jr, Cibele Lima Belico Suzuki

Published Date October 2010 Volume 2010:4 Pages 1165—1171

DOI http://dx.doi.org/10.2147/OPTH.S6289

Published 7 October 2010

Emilio Rintaro Suzuki Jr, Cibele Lima Belico Suzuki
Instituto de Olhos Pampulha, Belo, Horizonte, Minas Gerais, Brazil
Abstract: Travoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension for reducing intraocular pressure (IOP). The IOP-lowering efficacy of travoprost has been shown to be similar to that of other prostaglandins, including latanoprost and bimatoprost. When compared with fixed combinations of timolol and either latanoprost or dorzolamide, travoprost alone can reduce mean IOP in a similar or superior manner. Concomitant therapy of travoprost and timolol can reach even greater IOP reductions than fixed combinations at some time points, but with no difference in the early morning, when IOP is usually higher. In addition, the long duration of action of travoprost can also provide better control of IOP fluctuation, probably due to its stronger prostaglandin F receptor mechanism. The side effects of travoprost do not represent a risk to the vision or health of the patient. The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma.

Keywords: travoprost, prostaglandin, glaucoma
Corrigendum

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

A case of typical pulmonary carcinoid tumor treated with bronchoscopic therapy followed by lobectomy

Porpodis K, Karanikas M, Zarogoulidis P, Kontakiotis T, Mitrakas A, Esebidis A, Konoglou M, Domvri K, Iordanidis A, Katsikogiannis N, Courcoutsakis N, Zarogoulidis K.

Journal of Multidisciplinary Healthcare 2012, 5:47-51

Published Date: 16 February 2012

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Lyme disease: the next decade

Raphael B Stricker, Lorraine Johnson

Infection and Drug Resistance 2011, 4:1-9

Published Date: 7 January 2011

Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant

Jane S Myung, Grant D Aaker, Szilárd Kiss

Clinical Ophthalmology 2010, 4:1423-1426

Published Date: 6 December 2010

Central serous papillopathy by optic nerve head drusen

Ana Marina Suelves, Ester Francés-Muñoz, Roberto Gallego-Pinazo, et al

Clinical Ophthalmology 2010, 4:1379-1382

Published Date: 25 November 2010

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells

Masahiko Ayaki, Atsuo Iwasawa, Yoichi Inoue

Clinical Ophthalmology 2010, 4:1217-1222

Published Date: 15 October 2010

Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs

Jordana K Schmier, Edmund C Lau, David W Covert

Clinical Ophthalmology 2010, 4:1137-1143

Published Date: 29 September 2010

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009